Outcome of MC3 Ring Annuloplasty for Functional Tricuspid Regurgitation
1 other identifier
observational
105
0 countries
N/A
Brief Summary
This study includes 105 patients who underwent repair for ≥ moderate tricuspid regurgitation (TR) during mitral valve replacement for rheumatic valve disease. Between January 2016 and December 2018, a group of 23 patients underwent ring annuloplasty with Edward MC3 rings were compared to another group of 82 patients underwent standard suture (DeVega) repair. The primary outcome was residual TR (≥ moderate TR).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jan 2016
Typical duration for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2018
CompletedFirst Submitted
Initial submission to the registry
August 31, 2019
CompletedFirst Posted
Study publicly available on registry
September 6, 2019
CompletedSeptember 6, 2019
September 1, 2019
3 years
August 31, 2019
September 4, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Residual tricuspid regirgitation (TR)
residual TR is defined when there is moderate or above degree of TR at the last follow-up echocardiography of the patient
3-33 months
Study Arms (2)
DeVega
The DeVega repair is performed when the patient had minimal annular dilation and lower severity of pulmonary hypertension
MC3 ring
MC3 ring annuloplasty is performed in patients with severe tricuspid annular dilation and severe pulmonary hypertension
Interventions
Tricuspid valve repair during mitral valve replacement for rheumatic heart disease using suture (DeVega) repair or ring annuloplasty
Eligibility Criteria
Adult patients who underwent repair for functional tricuspid regurgitation during mitral valve replacement for rheumatic valve disease
You may qualify if:
- Rheumatic mitral valve disease
- Surgery for mitral valve replacement
- Severe functional tricuspid regurgitation
- Moderate functional tricuspid regurgitation with annular dilatation \> 40 mm
- Moderate functional tricuspid regurgitation with preoperative systolic pulmonary artery pressure (SPAP) \>50 mmHg
You may not qualify if:
- Patients with non-rheumatic mitral disease
- Combined mitral and aortic valve replacement
- Mitral valve repair
- Concomitant coronary artery or aortic surgery
- Mild or organic tricuspid regurgitation
- Emergency surgery
- Reoperations
- Invalid or missed data
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Minia Universitylead
Study Officials
- PRINCIPAL INVESTIGATOR
Yasser A Kamal, MD
Minia University
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Target Duration
- 3 Months
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
August 31, 2019
First Posted
September 6, 2019
Study Start
January 1, 2016
Primary Completion
December 31, 2018
Study Completion
December 31, 2018
Last Updated
September 6, 2019
Record last verified: 2019-09